Condition: Acute Myeloid Leukemia · Sponsor: Centre Leon Berard
This is a prospective, multicenter, clinical-biological cohort study. Its objective is to assess the pharmacokinetics-pharmacodynamics (PK-PD) of venetoclax (VEN) in patients with Acute Myeloid Leukemia (AML). This study involves only minimal risks and constraints related to the collection of biological samples (blood samples for PK testing) and the collection of clinical data. Therapeutic management of patients participating in this study is not changed. A total of 100 patients will be included in the study over a 12-month period. A maximum of 21 additional samples are planned, with a maximum of 12 mL of blood per sampling day (4 mL at each sampling time) for PK dosing of venetoclax.
This description comes directly from the study's public registry record.
Michaël Philippe · +33478782666 · michael.philippe@lyon.unicancer.fr
Amine Belhabri, MD · amine.belhabri@lyon.unicancer.fr
Always discuss trial participation with your own doctor first.
| Centre Hospitalier Pierre Oudot | Bourgoin, France, France | Recruiting |
| CHU de Grenoble | Grenoble, France | Recruiting |
| Centre Leon Berard | Lyon, France | Recruiting |
| CHU de Saint-Étienne | Saint-Etienne, France | Recruiting |
| Hôpitaux Nord-Ouest - Villefranche-sur-Saône | Villefranche-sur-Saône, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07243483